Q1 Earnings Forecast for LVTX Issued By Leerink Partnrs

LAVA Therapeutics (NASDAQ:LVTX) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for LAVA Therapeutics in a report released on Thursday, December 12th. Leerink Partnrs analyst D. Graybosch forecasts that the company will earn ($0.23) per share for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for LAVA Therapeutics’ current full-year earnings is ($1.28) per share. Leerink Partnrs also issued estimates for LAVA Therapeutics’ Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS and Q4 2025 earnings at ($0.23) EPS.

Other equities analysts have also recently issued reports about the stock. Leerink Partners reissued a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. JMP Securities reissued a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Finally, Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, LAVA Therapeutics currently has a consensus rating of “Hold” and an average target price of $4.67.

LAVA Therapeutics Stock Down 8.1 %

NASDAQ:LVTX opened at $1.02 on Monday. LAVA Therapeutics has a twelve month low of $1.00 and a twelve month high of $6.47. The firm has a market capitalization of $25.86 million, a price-to-earnings ratio of -0.99 and a beta of 0.43. The stock’s 50 day moving average price is $1.67 and its two-hundred day moving average price is $1.81.

Hedge Funds Weigh In On LAVA Therapeutics

Several large investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in shares of LAVA Therapeutics during the 3rd quarter worth about $32,000. XTX Topco Ltd bought a new position in LAVA Therapeutics in the 2nd quarter valued at about $55,000. Finally, Pathway Financial Advisors LLC lifted its position in LAVA Therapeutics by 328.6% during the second quarter. Pathway Financial Advisors LLC now owns 60,000 shares of the company’s stock worth $108,000 after acquiring an additional 46,000 shares during the last quarter.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.